<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04037904</url>
  </required_header>
  <id_info>
    <org_study_id>B-1509/316-302</org_study_id>
    <nct_id>NCT04037904</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up of Interleukin-1B and H+,K+-ATPase mRNA Expression After Helicobacter Pylori Eradication</brief_title>
  <official_title>Long-term Follow-up of Interleukin-1B and H+,K+-ATPase mRNA Expression After Helicobacter Pylori Eradication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will evaluate the long-term changes of gastric H+, K+-adenosine triphosphatase (H+,
      K+-ATPase) and Interleukin-1B mRNA expression according to Helicobacter pylori (H.pylori)
      infection and intestinal metaplasia and investigate the long-term effect of H. pylori
      eradication
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      H. pylori suppresses gastric acid secretion by repressing gastric acid pump, H+, K+-ATPase,
      and stimulating Interleukin-1B. In this study, we will evaluate the expression of H+,
      K+-ATPase and Interleukin-1B mRNA according to H. pylori infection and intestinal metaplasia
      in controls and patients with gastric cancer. In addition, we observe the changes of H+,
      K+-ATPase and Interleukin-1B mRNA expression over 5 years after H. pylori eradication.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2006</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Interleukin-1B and H+,K+-ATPase mRNA expression</measure>
    <time_frame>1 year</time_frame>
    <description>Gastric Interleukin-1B and H+,K+-ATPase mRNA expression in subjects with and without H. pylori infection at baseline, and changes of Interleukin-1B and H+,K+-ATPase mRNA expression with time in subjects without H. pylori infection and subjects who underwent H. pylori eradication successfully.
Gastric Interleukin-1B and H+,K+-ATPase mRNA expression measured by reverse transcription polymerase chain reaction, using the gastric mucosa specimen obtained during esophagogastroduodenoscopy</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>H. pylori negative group</arm_group_label>
    <description>Subjects who have not have H. pylori infection, and had not receive H. pylori eradication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H. pylorieradicated group</arm_group_label>
    <description>Subjects who have had H. pylori infection currently and received successful H. pylori eradication according to appropriated indication</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Controls and patients with gastric dysplasia or gastric cancer who received
        esophagogastroduodenoscopy and underwent H. pylori tests
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Controls who did not have any evidence of gastric cancer, gastric dysplasia,
             esophageal tumor, peptic ulcer and lymphoma on esophagogastroduodenoscopy

          -  Patients with gastric dysplasia or gastric cancer who diagnosed with gastric dysplasia
             or early gastric cancer in the final pathological report

        Exclusion Criteria:

          -  Subjects with previous eradication treatment for H. pylori

          -  Subjects with previous gastrectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nayoung Kim, M.D., Ph.D.</last_name>
    <phone>+82-31-787-7008</phone>
    <email>nayoung49@empas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nayoung Kim, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2019</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Nayoung Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Interleukin-1 beta</keyword>
  <keyword>Gastric H+, K+- APTase</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

